[{"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-001", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed123.jsonl", "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n1. Recurrent calcium oxalate kidney stones\n2. Acute pancreatitis (lipase 1200 U/L)\n3. Elevated calcium (11.8 mg/dL, normal ~8.5-10.5)\n4. Elevated PTH (85 pg/mL, normal 10-65)\n5. CT shows diffuse gland enlargement without necrosis or ductal dilation\n6. Not on lithium or thiazides\n\nAnalysis:\n\nThe combination of elevated calcium + elevated PTH + recurrent kidney stones is pathognomonic for primary hyperparathyroidism.\n\nWhy hyperparathyroidism causes pancreatitis:\n- Hypercalcemia is a well-established cause of acute pancreatitis\n- Calcium oxalate stones are characteristic of hyperparathyroidism (due to hypercalcemia and hypercalciuria)\n- The mechanism involves calcium-mediated activation of pancreatic enzymes\n\nRuling out other options:\n\nB. Autoimmune pancreatitis: Would typically show ductal dilation, irregular narrowing, or other characteristic features on imaging. No mention of IgG4 elevation or autoimmune markers.\n\nC. Hereditary pancreatitis: No family history mentioned; doesn't explain the hypercalcemia and elevated PTH.\n\nD. Hypertriglyceridemia: No mention of elevated triglycerides; doesn't explain the metabolic abnormalities.\n\nE. Gastrinoma/ZES: Doesn't explain hypercalcemia or elevated PTH; would present with GI symptoms.\n\nA. Primary hyperparathyroidism: Perfectly explains:\n- Elevated calcium and PTH (diagnostic)\n- Recurrent kidney stones (from hypercalcemia)\n- Acute pancreatitis (hypercalcemia is a known trigger)\n- CT findings consistent with acute pancreatitis\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-002", "question": "A 52-year-old man with alcohol-related cirrhosis presents with acute upper GI bleeding. During emergent endoscopy, active spurting is seen from a large duodenal ulcer in the posterior bulb. After epinephrine injection and placement of two through-the-scope clips, bleeding continues. The following day, he develops fever and severe abdominal pain. CT shows retroperitoneal air and fluid tracking along the right psoas muscle. What is the most appropriate management?", "options": ["Angiographic embolization of the gastroduodenal artery", "Emergency laparotomy with duodenal diversion", "Percutaneous drainage of the retroperitoneal collection", "Repeat endoscopy with over-the-scope clip placement", "IV antibiotics and serial abdominal exams"], "answer": "B", "answer_index": 1, "explanation": "This scenario describes a posterior duodenal ulcer perforation into the retroperitoneum following endoscopic intervention. Given the ongoing bleeding and established contamination, definitive surgical management with duodenal diversion (e.g., Graham patch closure with gastrodujunostomy) is required. Angioembolization would address bleeding but not the perforation. Percutaneous drainage cannot control the duodenal leak. Repeat endoscopy is contraindicated with known perforation. Antibiotics alone would lead to uncontrolled sepsis.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-016", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "B", "model_outputs": "Let me work through this case systematically.\n\nClinical Scenario:\n- 52-year-old with alcohol-related cirrhosis\n- Acute upper GI bleeding from posterior duodenal ulcer\n- Failed endoscopic therapy (epinephrine + 2 clips, bleeding continues)\n- Next day: fever, severe abdominal pain\n- CT findings: retroperitoneal air and fluid along right psoas\n\nKey Finding - Perforation:\nThe retroperitoneal air and fluid collection indicate a duodenal perforation has occurred. This is a surgical emergency.\n\nAnalysis of Options:\n\nA. Angiographic embolization of the gastroduodenal artery\n- Appropriate for bleeding control in failed endoscopy\n- However, does NOT address the perforation\n- Perforation requires surgical intervention\n\nB. Emergency laparotomy with duodenal diversion\n- Addresses both the bleeding AND the perforation\n- Standard surgical approach for perforated duodenal ulcer\n- Duodenal diversion (gastrojejunostomy, vagotomy, or pyloric exclusion) is appropriate\n- This is the definitive treatment for this complication\n\nC. Percutaneous drainage of the retroperitoneal collection\n- May be considered for contained collections\n- Does NOT address the ongoing perforation or bleeding\n- Inadequate as sole therapy\n\nD. Repeat endoscopy with over-the-scope clip\n- Endoscopy is contraindicated with perforation\n- Risk of further contamination and worsening\n\nE. IV antibiotics and serial abdominal exams\n- Conservative management inappropriate for perforation\n- Patient has fever and severe pain indicating peritonitis/sepsis\n- Perforation requires urgent surgical intervention\n\nConclusion:\nThe patient has a perforated duodenal ulcer with retroperitoneal contamination. This is a surgical emergency requiring laparotomy. Duodenal diversion is the standard surgical approach for perforated duodenal ulcers, especially in the setting of failed endoscopic therapy.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-003", "question": "A 48-year-old woman with a history of systemic lupus erythematosus (SLE) on hydroxychloroquine and low-dose prednisone presents with 3 weeks of progressive dyspnea on exertion and dry cough. High-resolution CT shows diffuse ground-glass opacities with superimposed fine reticulation and subpleural sparing. Bronchoalveolar lavage reveals lymphocytic predominance (65%) with CD4:CD8 ratio of 0.8. Pulmonary function tests show a restrictive pattern with severely reduced DLCO (38% predicted). Which of the following is the most appropriate next step in management?", "options": ["Initiate high-dose intravenous methylprednisolone followed by oral prednisone 1 mg/kg/day", "Add mycophenolate mofetil to current immunosuppression", "Discontinue hydroxychloroquine and observe for 4 weeks", "Perform surgical lung biopsy to confirm usual interstitial pneumonia pattern", "Start rituximab therapy without additional testing"], "answer": "B", "answer_index": 1, "explanation": "The presentation is classic for lymphocytic interstitial pneumonia (LIP) associated with SLE, characterized by ground-glass opacities with reticulation, lymphocytic BAL, and low CD4:CD8 ratio. LIP in connective tissue disease typically requires more aggressive immunosuppression beyond steroids alone. Mycophenolate mofetil is the preferred steroid-sparing agent for SLE-associated interstitial lung disease with this pattern. High-dose steroids alone (A) are insufficient for progressive LIP. Hydroxychloroquine cessation (C) is unlikely to reverse established ILD. Surgical biopsy (D) is unnecessary with characteristic HRCT and BAL findings. Rituximab (E) is reserved for refractory cases after conventional immunosuppression fails.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed124-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed124.jsonl", "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 48-year-old woman with SLE on hydroxychloroquine and low-dose prednisone\n- 3 weeks of progressive dyspnea and dry cough\n- HRCT: ground-glass opacities with fine reticulation and subpleural sparing\n- BAL: lymphocytic predominance (65%) with CD4:CD8 ratio of 0.8\n- PFTs: restrictive pattern with severely reduced DLCO (38%)\n\nDiagnosis:\nThis clinical picture is consistent with SLE-associated interstitial lung disease (SLE-ILD), specifically lymphocytic interstitial pneumonia (LIP) or nonspecific interstitial pneumonia (NSIP).\n\nKey diagnostic clues:\n- The BAL pattern (lymphocytic predominance with low CD4:CD8 ratio of 0.8) is typical of SLE-ILD\n- Ground-glass opacities with fine reticulation and subpleural sparing are characteristic\n- Severely reduced DLCO indicates significant parenchymal involvement\n- The patient is already on hydroxychloroquine and low-dose prednisone, suggesting inadequate disease control\n\nEvaluation of Options:\n\nA. High-dose IV methylprednisolone followed by oral prednisone 1 mg/kg/day\n- This is appropriate for active, progressive SLE-ILD\n- The patient has progressive symptoms despite current therapy\n- High-dose corticosteroids are first-line for SLE-ILD\n- This is the standard initial approach\n\nB. Add mycophenolate mofetil\n- While MMF is used in SLE-ILD, it's typically added after initial corticosteroid therapy or for steroid-sparing purposes\n- Not the first-line initial management\n\nC. Discontinue hydroxychloroquine\n- Inappropriate; hydroxychloroquine is beneficial in SLE\n- No indication to discontinue\n\nD. Surgical lung biopsy\n- The clinical and radiologic findings are characteristic enough for SLE-ILD\n- Biopsy is not necessary for diagnosis in this context\n- Would delay necessary treatment\n\nE. Start rituximab\n- Not first-line therapy for SLE-ILD\n- Reserved for refractory cases\n\nThe answer is A"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-004", "question": "A 35-year-old woman with tuberous sclerosis complex develops rapidly progressive renal insufficiency. Imaging shows massively enlarged kidneys with innumerable angiomyolipomas, the largest measuring 8 cm. What is the most appropriate intervention to preserve renal function?", "options": ["Selective arterial embolization of the dominant tumors", "Initiation of everolimus therapy", "Bilateral nephrectomy with dialysis initiation", "Cryoablation of the largest angiomyolipomas", "Radical nephrectomy of the more affected kidney"], "answer": "B", "answer_index": 1, "explanation": "In TSC with diffuse angiomyolipomatosis causing renal failure, everolimus (an mTOR inhibitor) is first-line therapy as it targets the underlying pathophysiology, can reduce tumor size by over 50%, and preserves renal function better than procedural interventions. Embolization or ablation would be impractical for innumerable tumors and could accelerate renal decline. Nephrectomy should be avoided unless absolutely necessary for hemorrhage control. Everolimus addresses the systemic nature of TSC renal involvement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-017", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "B", "model_outputs": "Let me work through this systematically.\n\nKey Clinical Features:\n- 35-year-old woman with tuberous sclerosis complex (TSC)\n- Rapidly progressive renal insufficiency\n- Massively enlarged kidneys with innumerable angiomyolipomas\n- Largest tumor is 8 cm\n\nUnderstanding the Problem:\nAngiomyolipomas (AMLs) are benign tumors commonly associated with TSC. The issue here is:\n1. Multiple/innumerable tumors (not just one or two)\n2. Rapidly progressive renal dysfunction\n3. Massively enlarged kidneys\n4. This suggests diffuse parenchymal involvement\n\nAnalyzing Options:\n\nA. Selective arterial embolization - Good for preventing hemorrhage from large AMLs, but won't address the underlying progressive renal dysfunction from diffuse tumor burden and parenchymal loss.\n\nB. Everolimus therapy - This is an mTOR inhibitor. TSC1/TSC2 mutations lead to mTOR pathway hyperactivation. Everolimus has been shown to:\n- Reduce AML size and number\n- Slow progression of renal disease in TSC patients\n- Preserve renal function\n- Is the standard medical therapy for TSC-associated AMLs causing renal dysfunction\n- FDA-approved for this indication\n\nC. Bilateral nephrectomy - Too aggressive; would immediately require dialysis and is not first-line for preserving function.\n\nD. Cryoablation - Suitable for isolated tumors, not for innumerable diffuse AMLs.\n\nE. Radical nephrectomy of more affected kidney - Destructive approach; doesn't address the bilateral disease and progressive dysfunction.\n\nRationale:\nWith innumerable AMLs causing progressive renal dysfunction in a TSC patient, the goal is to slow disease progression and preserve remaining renal function. Everolimus (mTOR inhibitor) is the evidence-based, FDA-approved therapy that addresses the underlying pathophysiology of TSC-related AMLs and has demonstrated efficacy in preserving renal function.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "source_question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251219T221819110Z_deepseek-v3.2_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T221819110Z_deepseek-v3.2_seed133.jsonl", "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n- 62-year-old with essential thrombocythemia (ET), JAK2 V617F-positive\n- On hydroxyurea\n- Acute stroke (left MCA territory infarction)\n- Platelet count 450,000/μL (relatively controlled)\n- Multiple small enhancing lesions on MRI brain\n- Negative blood cultures, no endocarditis on echo\n\nAnalysis of Options:\n\nA. Nonbacterial thrombotic endocarditis (NBTE)\n- NBTE typically presents with vegetations on echo (not seen here)\n- Blood cultures negative (expected)\n- However, NBTE is associated with hypercoagulable states and malignancy\n- ET itself is a myeloproliferative disorder with inherent thrombotic risk\n\nB. Leukoencephalopathy from hydroxyurea\n- Hydroxyurea can cause leukoencephalopathy\n- However, this typically presents more insidiously\n- Doesn't explain acute stroke presentation\n- Multiple enhancing lesions are not typical for hydroxyurea toxicity\n\nC. Transformation to AML with CNS involvement\n- Possible but less likely given current presentation\n- Would expect other systemic signs\n\nD. Cerebral vasculitis secondary to JAK2 mutation\n- JAK2 V617F-positive ET is associated with thrombotic complications\n- Can cause vasculitis and stroke\n- Multiple enhancing lesions could represent vasculitis\n- This is a known complication of myeloproliferative neoplasms\n\nE. Paradoxical embolism through PFO\n- Echo showed no vegetations\n- Doesn't explain multiple enhancing lesions\n- Less likely given the clinical picture\n\nMost Likely Diagnosis:\nThe combination of JAK2 V617F-positive ET with acute stroke and multiple enhancing brain lesions suggests cerebral vasculitis as a complication of the myeloproliferative disorder. JAK2-positive ET is known to cause vasculitic complications affecting the CNS. The multiple enhancing lesions on MRI with contrast are consistent with vasculitis rather than simple thromboembolism.\n\nThe answer is D"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-006", "question": "A 28-year-old woman develops recurrent sinopulmonary infections and bronchiectasis. Workup reveals absent IgA, markedly reduced IgG and IgM, and absent B cells on flow cytometry. Genetic testing identifies a mutation in the λ5 surrogate light chain gene. Which specific immunological abnormality explains her infection pattern?", "options": ["Failure of heavy chain rearrangement in pre-B cells", "Defective VDJ recombination due to RAG deficiency", "Absence of the pre-B cell receptor complex signaling", "Mutation in the BLNK adapter protein preventing PLCγ activation", "Loss of BTK enzyme function disrupting B cell maturation"], "answer": "C", "answer_index": 2, "explanation": "The λ5 gene encodes part of the surrogate light chain critical for pre-B cell receptor formation. Without functional pre-BCR signaling, B cells fail to proliferate and mature at the pre-B cell stage, causing the arrested development seen here. This is distinct from Bruton's tyrosine kinase deficiency (which affects later signaling) or RAG deficiencies (which impair initial recombination). The specific λ5 mutation explains the profound B cell deficiency and hypogammaglobulinemia.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "C", "model_outputs": "Let me work through this systematically.\n\nKey Clinical Findings:\n- Recurrent sinopulmonary infections and bronchiectasis\n- Absent IgA, markedly reduced IgG and IgM\n- Absent B cells on flow cytometry\n- Mutation in λ5 surrogate light chain gene\n\nUnderstanding λ5 (Lambda-5):\n- λ5 is a component of the surrogate light chain (SLC)\n- The surrogate light chain pairs with the heavy chain to form the pre-B cell receptor (pre-BCR)\n- The pre-BCR complex consists of: heavy chain + surrogate light chain (λ5 + VpreB) + Igα/Igβ signaling molecules\n\nPathophysiology of λ5 Mutation:\n- Without functional λ5, the surrogate light chain cannot form properly\n- This prevents assembly of the pre-B cell receptor complex\n- The pre-BCR is essential for:\n  - Signaling in pre-B cells\n  - Proliferation and survival of pre-B cells\n  - Progression from pro-B to pre-B stage\n  - Allowing heavy chain rearrangement to proceed\n\nWhy B cells are absent:\n- Without pre-BCR signaling, pre-B cells cannot survive and proliferate\n- B cell development is arrested at the pre-B cell stage\n- This results in absent mature B cells and no antibody production\n\nEvaluating Options:\n- A: Heavy chain rearrangement can occur, but without pre-BCR signaling, pre-B cells die\n- B: RAG genes are intact; VDJ recombination can initiate but cells don't survive\n- C: This is correct - λ5 is part of the pre-BCR complex; its absence prevents pre-BCR signaling\n- D: BLNK is downstream; the primary defect is pre-BCR assembly\n- E: BTK deficiency causes X-linked agammaglobulinemia but with some B cells present\n\nThe answer is C\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-007", "question": "A 44-year-old woman presents with 8 months of progressive proximal muscle weakness, heliotrope rash, and Gottron's papules. Muscle biopsy shows perfascicular atrophy and MAC deposition on capillaries. She tests positive for anti-MDA5 antibodies. Which of the following complications carries the highest immediate mortality risk?", "options": ["Aspiration pneumonia", "Cardiac conduction abnormalities", "Rapidly progressive interstitial lung disease", "Malignancy-associated deterioration", "Calcinosis universalis"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 antibody-positive dermatomyositis is strongly associated with rapidly progressive interstitial lung disease (RP-ILD), which has mortality exceeding 50% within 6 months despite treatment. This subtype shows characteristic skin findings but often minimal muscle involvement, with MAC deposition on capillaries. While aspiration (A) and cardiac issues (B) occur in myositis, RP-ILD is the most lethal complication in anti-MDA5 patients. Malignancy risk (D) is lower with anti-MDA5 than with anti-TIF1γ. Calcinosis (E) is chronic but not immediately life-threatening. Early recognition and aggressive immunosuppression for RP-ILD are critical in anti-MDA5 dermatomyositis.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed124.jsonl", "pred": "C", "model_outputs": "Let me work through this systematically.\n\nThe clinical presentation describes dermatomyositis (DM):\n- Heliotrope rash and Gottron's papules (pathognomonic skin findings)\n- Proximal muscle weakness\n- Muscle biopsy with perfascicular atrophy and MAC deposition on capillaries (characteristic of DM)\n- Anti-MDA5 antibodies (a specific autoantibody in DM)\n\nAnti-MDA5 antibodies are particularly associated with:\n- Clinically amyopathic dermatomyositis (CADM)\n- Rapidly progressive interstitial lung disease (RP-ILD)\n- Poor prognosis if lung involvement develops\n\nNow let's evaluate the complications for immediate mortality risk:\n\nA. Aspiration pneumonia - A serious complication but typically manageable with antibiotics if caught early\n\nB. Cardiac conduction abnormalities - Can occur in myositis but not the most common or immediately life-threatening complication in this context\n\nC. Rapidly progressive interstitial lung disease - Anti-MDA5 antibodies are strongly associated with RP-ILD, which can progress to respiratory failure within weeks to months. This is the leading cause of death in anti-MDA5+ DM patients. It can develop rapidly and lead to acute respiratory failure.\n\nD. Malignancy-associated deterioration - While DM is associated with malignancy, this is a longer-term concern\n\nE. Calcinosis universalis - A late complication that doesn't cause immediate mortality\n\nThe anti-MDA5 antibody positivity is the key clinical clue here. This antibody is strongly predictive of rapidly progressive interstitial lung disease, which is the most common cause of death in these patients and carries the highest immediate mortality risk due to rapid progression to respiratory failure.\n\nThe answer is C"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-008", "question": "A 30-year-old missionary presents with a slowly enlarging scalp lesion after returning from Bolivia. biopsy demonstrates lobulated granulomatous inflammation with rare 5-7 μm budding yeast. Culture on brain-heart infusion agar at 25°C shows cream-colored colonies that convert to yeast form at 37°C. What is the most appropriate antifungal therapy?", "options": ["Itraconazole for 6-12 months", "Amphotericin B lipid complex followed by itraconazole", "Voriconazole indefinitely", "Posaconazole with therapeutic drug monitoring", "Fluconazole for 3-6 months"], "answer": "A", "answer_index": 0, "explanation": "The presentation describes cutaneous granulomas caused by Paracoccidioides brasiliensis, endemic to Latin America. Itraconazole is first-line for non-severe disease, with 6-12 months treatment typically achieving cure. Amphotericin B is reserved for severe disseminated disease. Voriconazole has variable activity against Paracoccidioides. Fluconazole is less effective due to higher relapse rates. The dimorphic growth pattern and geographic history are classic for this infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-019", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "A", "model_outputs": "Let me work through this systematically.\n\nKey Clinical Features:\n- Geographic location: Bolivia (endemic fungal region)\n- Slowly enlarging scalp lesion\n- Histology: Lobulated granulomatous inflammation with 5-7 μm budding yeast\n- Culture: Cream-colored colonies at 25°C that convert to yeast form at 37°C (dimorphic fungus)\n\nFungal Identification:\nThe combination of:\n- South American origin (Bolivia)\n- Dimorphic fungus (mold at 25°C, yeast at 37°C)\n- 5-7 μm budding yeast\n- Scalp/skin presentation with granulomatous inflammation\n\nThis is classic for Paracoccidioides brasiliensis (paracoccidioidomycosis).\n\nTreatment Considerations:\n\nFor paracoccidioidomycosis:\n- Itraconazole is the first-line agent for chronic/localized disease (including cutaneous and lymphangitic forms)\n- Duration: typically 6-12 months for localized disease\n- It has excellent CNS penetration and tissue distribution\n- Amphotericin B is reserved for severe, disseminated, or acute disease\n- Voriconazole and posaconazole are alternatives but not first-line\n- Fluconazole is less effective than itraconazole\n\nClinical Presentation Analysis:\nThis patient has a slowly enlarging scalp lesion (localized cutaneous disease), not acute or disseminated disease. This is a chronic presentation typical of paracoccidioidomycosis.\n\nAnswer Selection:\nOption A (Itraconazole for 6-12 months) is the standard first-line therapy for localized paracoccidioidomycosis and matches the clinical presentation perfectly.\n\nThe answer is A"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-009", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed131.jsonl", "pred": "B", "model_outputs": "Let me work through this systematically.\n\nKey Clinical Features:\n- HER2-positive breast cancer with pancreatic metastasis\n- Achieved partial response on trastuzumab/pertuzumab/docetaxel\n- New pancreatic lesion: HER2 3+ by IHC but NO HER2 amplification by NGS\n- PIK3CA H1047R mutation present\n- Never received CDK4/6 inhibitor or everolimus\n- ER-/PR- status\n\nCritical Finding:\nThe discordance between HER2 IHC (3+) and NGS (no amplification) is important. This suggests HER2 protein overexpression without gene amplification, which may indicate reduced HER2 dependency or potential resistance mechanism.\n\nAnalysis of Options:\n\nA. Continue trastuzumab/pertuzumab + capecitabine\n- Patient already progressed on this regimen (new metastasis)\n- Not appropriate for progressive disease\n\nB. T-DXd (trastuzumab deruxtecan)\n- Excellent option for HER2-positive breast cancer progression\n- Works even with lower HER2 expression\n- Standard of care for HER2+ disease after progression on trastuzumab/pertuzumab\n- However, the NGS showing no HER2 amplification is concerning\n\nC. Lapatinib + capecitabine\n- Dual HER2 inhibition\n- Could be considered but less optimal than T-DXd for HER2+ disease\n\nD. Everolimus + exemestane\n- For hormone receptor-positive disease\n- Patient is ER-/PR-, so not appropriate\n\nE. Alpelisib + fulvestrant\n- Alpelisib is a PI3K inhibitor\n- Patient has PIK3CA mutation (H1047R)\n- Fulvestrant is for ER+ disease\n- Patient is ER-/PR-, so not appropriate\n\nThe Deciding Factor:\nThe PIK3CA H1047R mutation in the setting of HER2 discordance (IHC 3+ but no NGS amplification) suggests PI3K pathway activation may be driving resistance. However, the patient is ER-/PR-, making hormone therapy combinations inappropriate.\n\nFor HER2+ breast cancer with progression, T-DXd remains the standard next step and is most appropriate, as it's indicated for HER2-positive metastatic breast cancer after prior anti-HER2 therapy.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-010", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy / Immunology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed131.jsonl", "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n- CVID patient on monthly IVIG\n- Acute meningitis-like syndrome (headache, photophobia, neck stiffness)\n- Occurs 36 hours after IVIG infusion (temporal relationship)\n- LP findings: elevated opening pressure, low WBC (2/μL - unusually low), normal protein, low glucose ratio\n- Negative cultures and Gram stain\n- Normal MRI\n- Pattern: recurrent episodes, always within 48 hours of IVIG\n\nDiagnosis:\nThis is IVIG-associated aseptic meningitis (IVIG-AM), a known adverse reaction to IVIG that occurs in immunodeficient patients, particularly those with CVID. The temporal relationship to infusion, recurrent pattern, and negative cultures are classic.\n\nPathophysiology:\nIVIG-AM is thought to be related to:\n- High osmolality of certain IVIG formulations\n- Rapid infusion rates\n- Immune complex formation\n- Meningeal inflammation\n\nEvaluating Options:\n\nA. Switch to SCIG - SCIG bypasses the systemic circulation initially and has lower peak concentrations. This is actually a well-established approach for IVIG-AM prevention. SCIG maintains immune protection while avoiding the acute systemic exposure that triggers the reaction.\n\nB. High-dose corticosteroids - May help acutely but doesn't address the underlying mechanism and doesn't prevent recurrence reliably.\n\nC. Change IVIG product - Could help, but doesn't address the fundamental issue of systemic exposure in susceptible patients.\n\nD. Slower infusion rate - May help somewhat, but the patient has already had recurrent episodes despite presumably standard infusion practices.\n\nE. Replace with antibiotics - Inadequate immune protection for CVID patient.\n\nBest Answer:\nSCIG is the gold standard intervention for IVIG-AM in CVID patients. It provides:\n- Adequate immunoglobulin replacement\n- Avoidance of high peak serum concentrations\n- Prevention of the meningitis-triggering mechanism\n- Proven efficacy in preventing recurrence\n\nThe answer is (A)"}]